Applied DNA Schedules Fiscal 2019 Fourth Quarter Financial Results Conference Call for Thursday, December 12, 2019 at 4:30 PM...
December 05 2019 - 5:00AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it
plans to release financial results for its fiscal 2019 fourth
quarter ended September 30, 2019 after market close on Thursday,
December 12, 2019. In conjunction with the release, the Company has
scheduled a conference call at 4:30 p.m. Eastern Time that will
also be broadcast live over the Internet.
What: Applied DNA’s Fiscal 2019 Fourth Quarter Financial
Results Conference Call
When: Thursday, December 12, 2019, at 4:30 p.m. Eastern
Time
Where: Via phone by dialing +1 844-887-9402 or +1
412-317-6798 and ask to join the Applied DNA call; via webcast.
A telephonic replay of the conference call will be available for
one day and may be accessed by calling +1 877-344-7529 or +1
412-317-0088 with the passcode 10136194. The webcast will be
archived within the ‘Events and Presentations’ portion of the
‘Investors’ page to the company’s website.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping, and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and
warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements describe Applied DNA’s future plans, projections,
strategies and expectations, and are based on assumptions and
involve a number of risks and uncertainties, many of which are
beyond the control of Applied DNA. Actual results could differ
materially from those projected due to the substantial doubt
relating to Applied DNA’s ability to continue as a going concern,
our ability to successfully enter into commercial contracts for the
implementation of our CertainT® platform, the possibility of
failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, the Company’s history of net losses, limited
financial resources, limited market acceptance, the uncertainties
inherent in research and development, future clinical data and
analysis, including whether any of Applied DNA’s product candidates
will advance further in the preclinical research or clinical trial
process, and various other factors detailed from time to time in
Applied DNA’s SEC reports and filings, including our Annual Report
on Form 10-K filed on December 18, 2018, as amended, and our
subsequent quarterly reports on Form 10-Q filed on February 7,
2019, May 9, 2019 and August 13, 2019, and other reports we file
with the SEC, which are available at www.sec.gov. Applied DNA
undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances
after the date hereof to reflect the occurrence of unanticipated
events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191205005121/en/
Investor contact: Sanjay M. Hurry, LHA Investor
Relations, 212-838-3777, shurry@lhai.com Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Sep 2023 to Sep 2024